Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024 ...Middle East

VANCOUVER, BC, Jan. 22, 2024 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, presented positive Phase 2 safety and efficacy data in advanced metastatic colorectal cancer (mCRC) patients treated with BOLD-100 in...

Hence then, the article about bold therapeutics announces positive phase 2 safety and efficacy results for bold 100 in advanced metastatic colorectal cancer at asco gi 2024 was published today ( Monday 22/01/2024 - 04:48 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024 )

Also on site :

• The ‘imminent’ oil crisis isn’t at the pump—it’s under your hood
• Infighting, court battles could put long-hyped air taxi breakthrough in jeopardy
• Trump to step up Cuba regime change campaign – Axios